Sevelamer HCl

ApprovedSmall molecule

Novartis

Sevelamer HCl is one of 61 small molecule programs targeting Hyperphosphatemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperphosphatemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Renal OsteodystrophyActive, not recruiting

HyperphosphatemiaApproved

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Renal OsteodystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Sevelamer HCl

Novartis

Approved

2 2

Lorelco

Sanofi

Preclinical

1 3

Glucotrol

Pfizer

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Activase

Roche

Preclinical

—7

Miochol

BBausch Health Americas, Inc.

Preclinical

2 8

Epoetin Beta

Roche

Preclinical

5 9

Viagra

VViatris Specialty LLC

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease2 trials

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Completed· Novartis logo

Novartis·Phase 2·NCT00704483·321 enrolled

Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis

Completed· Novartis logo

Novartis·Phase 2·NCT00704678·203 enrolled

Renal Osteodystrophy1 trial

Regulation of Bone Formation in Renal Osteodystrophy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00560300·61 enrolled

Haemodialysis1 trial

Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

Completed·IIneos Healthcare Limited·Phase 2·NCT00436683·64 enrolled

Hyperphosphatemia1 trial

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Completed·CChugai Pharma Taiwan·Phase 4·NCT01755078·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sevelamer HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sevelamer HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sevelamer HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Sevelamer HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease2 trials

Renal Osteodystrophy1 trial

Haemodialysis1 trial

Hyperphosphatemia1 trial

References

Drug Info

Quick Facts

Related News